Update on Rivaroxaban

Update on Rivaroxaban

Show other versions (1)

Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need f...

Full description

Bibliographic Details
Main Authors: Osama Moussa, Dipankar Chattopadhyay, Vish Bhattacharya
Format: Article
Language:English
Published: SAGE Publishing 2010-01-01
Series:Clinical Medicine Insights: Blood Disorders
Online Access:https://doi.org/10.4137/CMBD.S5101
id doaj-9de1dc92c9744a9484d7311f2e3d16a1
record_format Article
spelling doaj-9de1dc92c9744a9484d7311f2e3d16a12020-11-25T03:31:53ZengSAGE PublishingClinical Medicine Insights: Blood Disorders1179-545X2010-01-01310.4137/CMBD.S5101Update on RivaroxabanOsama Moussa0Dipankar Chattopadhyay1Vish Bhattacharya2Department of General Surgery, Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK.Department of General Surgery, Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK.Department of General Surgery, Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK.Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment. Some of these newer drugs are in the advanced stages of clinical trials or have already completed them and thereby aim to provide more options in the management of thromboembolism. In the present review we discuss the currently available evidence supporting the use of these new anticoagulants, in particular rivaroxaban.https://doi.org/10.4137/CMBD.S5101
collection DOAJ
language English
format Article
sources DOAJ
author Osama Moussa
Dipankar Chattopadhyay
Vish Bhattacharya
spellingShingle Osama Moussa
Dipankar Chattopadhyay
Vish Bhattacharya
Update on Rivaroxaban
Clinical Medicine Insights: Blood Disorders
author_facet Osama Moussa
Dipankar Chattopadhyay
Vish Bhattacharya
author_sort Osama Moussa
title Update on Rivaroxaban
title_short Update on Rivaroxaban
title_full Update on Rivaroxaban
title_fullStr Update on Rivaroxaban
title_full_unstemmed Update on Rivaroxaban
title_sort update on rivaroxaban
publisher SAGE Publishing
series Clinical Medicine Insights: Blood Disorders
issn 1179-545X
publishDate 2010-01-01
description Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment. Some of these newer drugs are in the advanced stages of clinical trials or have already completed them and thereby aim to provide more options in the management of thromboembolism. In the present review we discuss the currently available evidence supporting the use of these new anticoagulants, in particular rivaroxaban.
url https://doi.org/10.4137/CMBD.S5101
work_keys_str_mv AT osamamoussa updateonrivaroxaban
AT dipankarchattopadhyay updateonrivaroxaban
AT vishbhattacharya updateonrivaroxaban
_version_ 1724571003858714624

Similar Items